Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Ark Genomic Revolution ETF sold Atai shares and bought Compass Pathways shares. The article cites Jefferies estimates of $1-2 billion peak sales for Atai’s BPL-003 and notes Compass’s COMP360 phase 3 results and potential 2026 NDA timing.
How this was made
The 30-second read
Why it matters
The acquisition is a direct M&A catalyst for ATAI and a pipeline expansion catalyst for LLY. Separately, the regulatory actions described (FDA priority voucher and finalized clinical trial guidance) are used to argue CMPS has a faster, more investable path to market.
Market read
Traders can act on deal-driven re-pricing for ATAI and pipeline/regulatory-driven repricing for CMPS, while LLY’s move is a longer-horizon capital allocation story.
What to watch
For LLY, milestone-heavy economics depend on clinical and regulatory success; for CMPS, cash runway helps, but launch readiness still hinges on both FDA review and DEA scheduling.
Background
The article frames a psychedelics regulatory reset and contrasts LLY’s acquisition of ATAI with Ark’s preference for CMPS based on proximity to commercialization.
Ticker impact
Eli Lilly agreed to acquire AtaiBeckley for $2.8B upfront plus up to $1B in milestones, expanding its psychedelics pipeline.
Likely positive medium-term bias, but magnitude depends on market confidence in Atai’s Phase 3 path and milestone probability.
The article provides deal economics and Atai’s lead Phase 3 asset, but does not include financing terms, guidance, or immediate earnings impact.
AtaiBeckley is being acquired by Eli Lilly for $2.8B upfront with up to $1B more in milestones, changing its standalone risk/reward.
Near-term upside bias toward deal completion expectations, with volatility around deal conditions.
The article states the acquisition price structure and that the deal is already agreed, which is typically the dominant driver for the target’s trading.
The article links FDA psychedelic review prioritization and a Compass CNPV to COMP360’s path, while noting Ark sold ATAI and bought CMPS.
Potentially positive as traders price earlier review timelines and rescheduling odds, but still binary on FDA/DEA outcomes.
The text includes specific regulatory actions (CNPV, finalized guidance) and COMP360 Phase 3 endpoint claims, but no new trial data or rescheduling decision date.
Market effects
Reinforces a thaw in psychedelic drug regulation, potentially improving sentiment and financing conditions across the TRD/psilocybin peer set.
Primarily US-focused regulatory catalysts (FDA/DEA) with spillover into US-listed biotech sentiment.
Could influence global biotech investors’ willingness to fund CNS/psychedelics programs if US review timelines compress.
Counterpoint
The regulatory optimism may be over-discounting binary outcomes: FDA review speed does not guarantee approval, and DEA rescheduling timing remains uncertain.
Key entities
- companyEli Lilly
Agreed to acquire AtaiBeckley for $2.8B upfront plus up to $1B milestones.
- companyAtaiBeckley
Target of the acquisition; lead asset BPL-003 in Phase 3 for TRD.
- companyCompass Pathways
Lead program COMP360 in Phase 3; article cites FDA CNPV and regulatory guidance changes.
- regulatorFDA
Issued a Commissioner's National Priority Voucher to Compass and finalized psychedelic clinical trial guidance.
- regulatorDEA
Rescheduling psilocybin from Schedule I is described as a condition for CMPS launch readiness.
